| Literature DB >> 30270909 |
Mary Warrell1, David A Warrell2, Arnaud Tarantola3.
Abstract
The aim of this review is to guide clinicians in the practical management of patients suffering from rabies encephalomyelitis. This condition is eminently preventable by modern post-exposure vaccination, but is virtually always fatal in unvaccinated people. In the absence of any proven effective antiviral or other treatment, palliative care is an imperative to minimise suffering. Suspicion of rabies encephalomyelitis depends on recognising the classic symptomatology and eliciting a history of exposure to a possibly rabid mammal. Potentially treatable differential diagnoses must be eliminated, notably other infective encephalopathies. Laboratory confirmation of suspected rabies is not usually possible in many endemic areas, but is essential for public health surveillance. In a disease as agonising and terrifying as rabies encephalomyelitis, alleviation of distressing symptoms is the primary concern and overriding responsibility of medical staff. Calm, quiet conditions should be created, allowing relatives to communicate with the dying patient in safety and privacy. Palliative management must address thirst and dehydration, fever, anxiety, fear, restlessness, agitation, seizures, hypersecretion, and pain. As the infection progresses, coma and respiratory, cardiovascular, neurological, endocrine, or gastrointestinal complications will eventually ensue. When the facilities exist, the possibility of intensive care may arise, but although some patients may survive, they will be left with severe neurological sequelae. Recovery from rabies is extremely rare, and heroic measures with intensive care should be considered only in patients who have been previously vaccinated, develop rabies antibody within the first week of illness, or were infected by an American bat rabies virus. However, in most cases, clinicians must have the courage to offer compassionate palliation whenever the diagnosis of rabies encephalomyelitis is inescapable.Entities:
Keywords: diagnosis; encephalomyelitis; palliation; rabies; treatment
Year: 2017 PMID: 30270909 PMCID: PMC6082067 DOI: 10.3390/tropicalmed2040052
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Samples and methods recommended for rabies diagnosis in patients
| Sample | Purpose | Method |
|---|---|---|
| Full thickness skin | Antigen detection | IFA test on frozen vertical section † |
| Saliva★ or throat swab | Virus isolation | Tissue culture |
| Serum | Neutralising antibody test | Presence of antibody is diagnostic in unvaccinated patients |
| CSF | Neutralising antibody test | Test in parallel with serum |
| Brain post-mortem: | Virus isolation | Tissue culture |
‡ Highest positivity rate; rabies antigen seen in nerve twiglets around the base of hair follicles by immunofluorescence (IFA) test; easiest sample for antigen detection, repeat daily at least x 3, until a diagnosis is confirmed; necropsies are taken with a long biopsy needle via the medial canthus of the eye through the superior orbital fissure; via the nose through the ethmoid bone; through the foramen magnum or open fontanelles in children; ° alternative: a direct rapid immunohistochemical test with biotinylated monoclonal antibodies and light microscopy.
Drugs for the palliative management of patients with confirmed or strongly suspected rabies encephalomyelitis that are included in the WHO Model List of Essential Medicines 20th List (March 2017) and WHO Model List of Essential Medicines for Children 6th List (March 2017). http://www.who.int/medicines/publications/essentialmedicines/en/ Recommended doses are taken from https://www.bnf.org/products/bnf-online/ and https://bnfc.nice.org.uk/.
| Indication | Drug | Route of administration | Dose: adult | Dose: paediatric |
|---|---|---|---|---|
| paracetamol | iv infusion over 15 minutes | 1 g every 4–6 h, maximum 4 g/24 h |
| |
| intrarectal | 1 g every 4–6 h, maximum 4 g/24 h | 125–500 mg every 4–6 h | ||
| ibuprofen | intrarectal | 300–400 mg 6–8 hrly | ||
| aspirin | intrarectal | 450–900 mg 4 hrly, maximum 3.6 g/day | ||
| diazepam | iv (slow! caution!) | 10 mg in 3–5 minutes, repeated 1–4 hrly | 0.1–0.3 mg/kg in 3–5 min, repeated 1–4 hrly to provide 2.4–12 mg/kg/24 h | |
| im (painful!) | 20 mg 2 hrly | 0.1–0.3 mg/kg 1–4 hrly | ||
| intrarectal | 10mg 1–4 hrly | 0.1–0.3 mg/kg 1–4 hrly | ||
| lorazepam | im or slow iv injection into large vein (slow! caution!) | 25–50 microg/kg 6 hrly | 25–50 microg/kg 6 hrly | |
| midazolam | im | 0.08 – 0.2 mg/kg repeated 1–4 hrly | 0.07–0.1 mg/kg repeated 1–4 hrly | |
| iv or sc injection | 2.5 mg hrly | |||
| sc infusion | 10–30 mg over 24 h by pump | |||
| intrarectal | 300–500 microg 1–4 hrly | |||
| haloperidol | im or sc injection | 5 mg hourly until calm, then 4 or 6 hrly and when necessary | age 1 month–12 y: 25–85 microg/kg/24 h | |
| iv or sc infusion | 5–15 mg/24 h | 12–18 y: 1.5–5 mg/24 h | ||
| chlorpromazine | deep im | 25–50 mg/6–8 hrly | 500 microg/kg 6–8 hrly | |
| intrarectal | 100 mg/6–8 hrly | |||
| hyoscine (scopolamine) hydrobromide | sc or iv injection | 400 microg 4 hrly | 10 microg/kg 4–8 hrly | |
| sc infusion | 1.2–2 mg/24 h | 40–60 microg/kg/24 h | ||
| morphine | slow iv, sc or im | 10 mg 4 hrly | ||
| intrarectal | 15–30 mg 4 hrly | 100 microg/kg | ||
| fentanyl | transdermal patch | 12–25 microg/h every 72 h | 12 microg/h every 72 h |